Δημοσιεύσεις – Ανακοινώσεις

• 6/2025: The impact of salvage radiotherapy in recurrent endometrial cancer: a review focusing on early-stage, endometrial cancer locoregional relapses
• 3/2025: Is it time to revisit the role of PD-L1 expression in assisting our treatment decisions?
• 3/2025: Acute phantosmia as the first manifestation of brain metastases in a patient with breast cancer. Case report
• 11/2024: Non-alcoholic Wernicke Encephalopathy in a Young Patient with Adenocarcinoma of the Colon: A Case Report and Review of the Literature
• 9/2024: Combining immunotherapy with PARP inhibitors. Is it possible to find the way through?
• 3/2024: Going with the flow while thinking outside the box: Case report of a primary extrapelvic clear cell endometrial carcinoma associated with cesarean scar endometriosis (forthcoming)
• 12/2023: PARP inhibitors in colorectal malignancies: a 2023 update
• 10/2023: Identification of a Novel TSC2 c.170G>A Missense Variant: A Case Report and Elaboration on the Yield of Targeted Options against Tuberous Sclerosis Complex Manifestations
• 3/2023: Is the patient actually failing on enzalutamide? A case report and issues to consider in enzalutamide-resistant oligoprogressive castrate-resistant prostate cancer
• 3/2023: Immune checkpoint inhibitors and combinations with other agents in cholangiocarcinoma
• 8/2022: Can thromboprophylaxis build a link for cancer patients undergoing surgical and / or chemotherapy treatment? The METHOS cohort study
• 2/2022: Systemic treatment of Ewing Sarcoma: Current Options and Future Perspectives
• 1/2022: Trimodality treatment in gastric and gastroesophageal junction cancers: Current approach and future perspectives
• 12/2021: Case report: Combination of Olaparib with Chemotherapy in a patient with ATM-deficient colorectal cancer
• 10/2021: Case Report: Adenocarcinoma of the larynx with later hepatocellular differentiation
• 8/2021: Perforated appendicitis induced by pembrolizumab – A case report and review of the literature
• 8/2021: An overview of current results with the Vincristine-Irinotecan-Temozolomide combination with or without Bevacizumab in pediatric, adolescense and adult solid tumors
• 7/2021: Central neurotoxicity induced by trastuzumab emtansine (T-DM1)-a case report
• 7/2021: High grade neuroendocrine carcinoma of the breast, first line and maintenance immunotherapy
• 6/2021: Immunotherapy for cholangiocarcinoma: a 2021 update
• 1/2021: Notable response of a young adult with recurrent glioblastoma multiforme to vincristine – irinotecan – temozolomide and bevacizumab
• 9/2020: Can thromboprophylaxis build a link for cancer patients undergoing surgical and / or chemotherapy treatment? Intermediate results from the METHOS study
• 1/2020: CNS Tumors in Adolescents and Young Adults: The Need for a Holistic Specialized Approach